

Sara Rundquist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4752494/publications.pdf>

Version: 2024-02-01

6
papers

66
citations

1937685

4
h-index

2272923

4
g-index

6
all docs

6
docs citations

6
times ranked

122
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. <i>Gut</i> , 2019, 68, 623-632.	12.1	22
2	Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 471-483.	3.7	18
3	Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110233.	3.2	17
4	Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1257-1263.	1.5	8
5	Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 642-643.	3.7	1
6	Letter: vedolizumab or a second anti-TNF"no difference in efficacy for primary biologic failures with IBD. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1046-1047.	3.7	0